BioNTech AG is Europe's largest privately held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases.

BioNTech combines all building blocks of individualized immunotherapy under one roof-from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based medicines through innovative chimeric antigen receptors and T-cell receptor-based products to novel checkpoint immunomodulators.

BioNTech was founded in 2008 and is based in Mainz, Rheinland-Pfalz, Germany.

BioNTech engages in developing individualized therapies for cancer and other diseases. It develops and commercializes a broad product pipeline using different scientific approaches and cutting-edge technology platforms. 

BioNTech's resarch platforms involve mRNA pharmaceuticals, cell and gene therapies, and protein therapies. BioNTech’s approach is validated by six top-tier corporate partnerships with Genentech, Genmab, Eli Lilly and Company, Sanofi, Pfizer, and Bayer Animal Health.

BioNTech is the first company worldwide to implement a medical genomics-driven design and GMP-approved manufacturing process for individual patient-specific therapies, to advance an mRNA-based individualized cancer vaccine targeting neoantigens into clinical trials, to enter the clinic with an mRNA-based individualized vaccine drawn from a warehouse of mRNAs encoding cancer-selective antigens, to test an intravenous formulation of a mRNA vaccine in clinical trials.

BioNTech is backed investors including Sanofi, Redmile Group, Invus, Janus Henderson Investors, MIG AG, and others.

BioNTech was valued at a whooping $2.3B during it's "Series A" funding of a $270M on Jan 4, 2018.